bioRxivBiochemistryPreprint
Structural models of full-length JAK2 kinase
P. Ayaz, H. Hammaren, J. Raivola, D. Sharon, S. Hubbard, O. Silvennoinen, Y. Shan, D. Shaw
Abstract
The protein JAK2 is a prototypical member of the Janus kinase family, and mediates signals from numerous cytokine receptors. The constitutively active V617F mutant of JAK2 is prevalent in many bone marrow disorders, blood cancers, and autoimmune diseases, and is an important drug target. Structures have been determined for each of the four individual domains making up JAK2, and for certain pairs of these domains, but no structure of full-length JAK2 is available, and thus the mechanisms underlying JAK2 regulation and the aberrant activity of the V617F mutant have been incompletely understood. Here we propose structural models of full-length JAK2 in both its active and inactive forms. Construction of these models was informed by long-timescale molecular dynamics simulations. Subsequent mutagenesis experiments showed that mutations at the putative interdomain interfaces modulated JAK2 activity. The models provide a structural basis for understanding JAK2 autoinhibition and activation, and suggest that the constitutive activity of the V617F mutant may arise from a dual effect of destabilizing the inactive conformation and stabilizing the active conformation.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Divergent conformational mechanisms of JAK2V617F and TYK2V678F mutations in Thrombocythemia and related disorders: Molecular Dynamics insights into pathway activation and therapeutic targeting
Tianwen Shao, Min Gan, … Shengjie Sun·bioRxiv·May 16, 2025
- The V617F mutation in JAK2 renders myeloid cells more sensitive to IL-6-mediated gp130 signaling
Henning Schurse, Marcelo A. S. Toledo, … Gerhard Müller‐Newen·bioRxiv·Oct 10, 2025
- Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms
A. Dunbar, R. L. Bowman, … R. L. Levine·bioRxiv·May 18, 2022
- Structural modeling of cytokine-receptor-JAK2 signaling complexes using AlphaFold Multimer
I. D. Pogozheva, S. Cherepanov, … A. Lomize·bioRxiv·Jun 14, 2023
- Selectivity and ranking of tight-binding JAK-STAT inhibitors using Markovian milestoning with Voronoi tessellations
A. A. Ojha, A. Srivastava, … R. E. Amaro·bioRxiv·Nov 10, 2022
- PH Domain-Mediated Autoinhibition and Oncogenic Activation of Akt
H. Bae, T. Viennet, … P. A. Cole·bioRxiv·May 25, 2022